MerLion Pharmaceuticals Pte Ltd, Announces Collaboration Agreement with Sankyo Co., Ltd
MerLion Pharmaceuticals Pte Ltd (MerLion) announced a three year drug discovery and development collaboration with Sankyo Co., Ltd. (Sankyo).
Under the collaboration, Sankyo will provide selected high throughput screens and additional assays to MerLion, who will provide access to its extensive sample collection and apply its screening and experienced natural products chemistry skills to the isolation of new chemical leads. MerLion and Sankyo will work in partnership throughout the lead discovery and optimisation stages of the collaboration. Sankyo will undertake clinical development and commercialisation of the discoveries.
"This agreement with Sankyo strengthens our existing relationships with Japan and key Japanese pharmaceutical companies" said Tony Buss, PhD, CEO of MerLion. "The partnership offers both Sankyo and MerLion unique opportunities to discover novel medicines from our diverse natural products chemistry and across a wide range of therapeutic areas."
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.